These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 38334807)

  • 41. Sexual health in patients with hematological malignancies: a neglected issue.
    Niscola P; Efficace F; Abruzzese E
    Support Care Cancer; 2018 Jun; 26(6):1699-1701. PubMed ID: 29502153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MUC1 in hematological malignancies.
    Stroopinsky D; Kufe D; Avigan D
    Leuk Lymphoma; 2016 Nov; 57(11):2489-98. PubMed ID: 27347699
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Advance of research on survivin in hematological malignancies--review].
    Xiong HX; Chen BA; Ding JH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):866-9. PubMed ID: 15631681
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
    Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
    Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Therapeutic approaches to hematological malignancies in adolescents and young adults].
    Sekimizu M
    Rinsho Ketsueki; 2018; 59(10):2273-2283. PubMed ID: 30305536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cell death in hematological tumors.
    Fulda S
    Apoptosis; 2009 Apr; 14(4):409-23. PubMed ID: 19130230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular basis of resistance to proteasome inhibitors in hematological malignancies.
    Niewerth D; Jansen G; Assaraf YG; Zweegman S; Kaspers GJ; Cloos J
    Drug Resist Updat; 2015 Jan; 18():18-35. PubMed ID: 25670156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CAR T-Cell Therapy in Hematological Malignancies.
    Haslauer T; Greil R; Zaborsky N; Geisberger R
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The hematologic malignancies. Leukemia, lymphoma, and myeloma.
    Freireich EJ; Keating M; Cabanillas F; Barlogie B
    Cancer; 1984 Dec; 54(11 Suppl):2741-50. PubMed ID: 6208991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cellular senescence and hematological malignancies: From pathogenesis to therapeutics.
    Hu D; Yuan S; Zhong J; Liu Z; Wang Y; Liu L; Li J; Wen F; Liu J; Zhang J
    Pharmacol Ther; 2021 Jul; 223():107817. PubMed ID: 33587950
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Advances in the target therapy of hematological malignancies].
    Niu T; Liu T
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):642-6. PubMed ID: 25286692
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Advances of study on activation of nuclear factor kappaB in hematological malignancies and its mechanism--review].
    Wang GP; Qi ZH; Chen FP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun; 13(3):518-23. PubMed ID: 15972157
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Review of relationship between tumor necrosis factor genetic polymorphism and hematological malignancies].
    Zhao HY; Chen YX
    Ai Zheng; 2003 Feb; 22(2):216-20. PubMed ID: 12600304
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monocytic Myeloid Derived Suppressor Cells in Hematological Malignancies.
    Palumbo GA; Parrinello NL; Giallongo C; D'Amico E; Zanghì A; Puglisi F; Conticello C; Chiarenza A; Tibullo D; Raimondo FD; Romano A
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683978
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Potential Roles and Advantages of Single Cell Sequencing in the Diagnosis and Treatment of Hematological Malignancies.
    Shi M; Dong X; Huo L; Wei X; Wang F; Sun K
    Adv Exp Med Biol; 2018; 1068():119-133. PubMed ID: 29943300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review.
    Zhang Y; Zhou F; Guan J; Zhou L; Chen B
    Biomolecules; 2023 Jan; 13(2):. PubMed ID: 36830619
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cancer incidence in France over the 1980-2012 period: Hematological malignancies.
    Le Guyader-Peyrou S; Belot A; Maynadié M; Binder-Foucard F; Remontet L; Troussard X; Bossard N; Monnereau A;
    Rev Epidemiol Sante Publique; 2016 Apr; 64(2):103-12. PubMed ID: 26973179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric antigen receptor T (CAR-T) cells: Novel cell therapy for hematological malignancies.
    Abbasi S; Totmaj MA; Abbasi M; Hajazimian S; Goleij P; Behroozi J; Shademan B; Isazadeh A; Baradaran B
    Cancer Med; 2023 Apr; 12(7):7844-7858. PubMed ID: 36583504
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel insights into the impact of the SUMOylation pathway in hematological malignancies (Review).
    Wang L; Qian J; Yang Y; Gu C
    Int J Oncol; 2021 Sep; 59(3):. PubMed ID: 34368858
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies.
    Zhu J; Hou T; Mao X
    Drug Discov Today; 2015 Aug; 20(8):988-94. PubMed ID: 25857437
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.